Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons ≥18 Years Old

Journal of Infectious Diseases

Volumn 212, Issue 4, 2015, Pages 552-561

  Keitel, Wendy A ^a   Jackson, Lisa A ^b   Edupuganti, Srilatha ^c,d   Winokur, Patricia L ^e,f   Mulligan, Mark J ^c,d   Thornburg, Natalie J ^g,h   Patel, Shital M ^a   Rouphael, Nadine G ^c,d   Lai, Lilin ^c,d   Bangaru, Sandhya ^g,h   McNeal, Monica M ⁱ   Bellamy, Abbie R ^j   Hill, Heather R ^j  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b GROUP HEALTH RESEARCH INSTITUTE   (United States)

^c EMORY UNIVERSITY   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF IOWA   (United States)

^f VA Health Care System   (United States)

^g VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^h Immunology/Microbiology   (United States)

ⁱ UNIVERSITY OF CINCINNATI   (United States)

^j EMMES CORPORATION   (United States)

more..

Author keywords

H3N2 variant; immune responses; immunization; influenza; pandemic

Indexed keywords

IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; NEUTRALIZING ANTIBODY; IMMUNOGLOBULIN G; VIRUS ANTIBODY;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CROSS REACTION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEMAGGLUTINATION INHIBITION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMORAL IMMUNITY; IMMUNOGENICITY; INFLUENZA A (H3N2); INFLUENZA VACCINATION; INFLUENZA VIRUS A H3N2; MALE; MEMORY CELL; NONHUMAN; NORMAL HUMAN; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT; VIRION; ADOLESCENT; B LYMPHOCYTE; BLOOD; IMMUNOLOGY; INFLUENZA A VIRUS (H3N2); INFLUENZA, HUMAN; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, VIRAL; B-LYMPHOCYTES; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84939628988     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv056     Document Type: Article

References (27)

1. CDC. Update: influenza A (H3N2)v transmission and guidelines-five states, 2011. MMWR Morb Mortal Wkly Rep 2012; 60:1741-4.
2. CDC. Swine-origin influenza A (H3N2) virus infection in two children-Indiana and Pennsylvania, July-August 2011. MMWR Morb Mortal Wkly Rep 2011; 60:1213-5.
3. CDC. Limited human-to-human transmission of novel influenza A(H3N2) virus-Iowa, November 2011. MMWR Morb Mortal Wkly Rep 2011; 60:1615-7.
4. Myers KP, Olsen CW, Gray GC. Cases of swine influenza in humans: a review of the literature. Clin Infect Dis 2007; 44:1084-8.
5. Lindstrom S. Human infectionswith novel reassortant influenzaA(H3N2)v viruses, United States, 2011. Emerg Infect Dis 2012; 18:834-7.
6. CDC. Outbreak of influenza A (H3N2) virus among persons and swine at a county fair-Indiana, July 2012. MMWR Morb Mortal Wkly Rep 2012; 61:561.
7. CDC. CDC reports cases 18-29 of H3N2v virus infection; continues to recommend interim precautions when interacting with pigs. http://www.cdc.gov/flu/spotlights/h3n2vuscases.htm. Accessed 14 July 2014.
8. CDC. Case count: detected U.S. human infections with H3N2v by state since August 2011. http://www.cdc.gov/flu/swineflu/h3n2v-case-count.htm. Accessed 16 September 2014.
9. CDC. Antibodies cross-reactive to influenza A (H3N2) variant virus and impact of 2010-2011 seasonal influenza vaccine on cross-reactive antibodies-United States. MMWR Morb Mortal Wkly Rep 2012; 61:237-41.
10. Skowronski D, De Serres G, Janjua N, et al. Cross-reactive antibody to swine influenza A(H3N2) subtype virus in children and adults before and after immunisation with 2010/11 trivalent inactivated influenza vaccine in Canada, August to November 2010. Euro Surveill 2012; 17:20066.
11. Skowronski DM, Janjua NZ, De Serres G, et al. Cross-reactive and vaccine-induced antibody to an emerging swine-origin variant of influenza A virus subtype H3N2 (H3N2v). J Infect Dis 2012; 206:1852-61.
12. Chen WH, Winokur PL, Edwards KM, et al. Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009. Vaccine 2012; 30:4240-8.
13. Lu Y, Jacobson DL, Ashworth LA, et al. Immune response to influenza vaccine in children with inflammatory bowel disease. Am J Gastroenterol 2009; 104:444-53.
14. Rowe T, Abernathy RA, Hu-Primmer J, et al. Detection of antibody to avian influenza A(H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999; 37:937-43.
15. Schlaudecker EP, Steinhoff MC, Omer SB, et al. IgA and neutralizing antibodies to influenza A virus in human milk: a randomized trial of antenatal influenza immunization. PLoS One 2013; 8:e7086714.
16. Crotty S, Aubert RD, Glidewell J, Ahmed R. Tracking human antigenspecific memory B cells: a sensitive and generalized ELISPOT system. J Immunol Methods 2004; 286:111-22.
17. Crotty S, Feigner P, Davies H, Glidewell J, Villareal L, Ahmed R. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol 2003; 171:4969-73.
18. Food and Drug Administration (FDA). Guidance for industry: clinical data needed to support the licensure of seasonal inactivated influenza vaccines. Silver Spring, MD: FDA, 2007.
19. Couch RB, Kasel JA. Immunity to influenza in man. Annu Rev Microbiol 1983; 37:529-49.
20. Talaat KR, Luke CJ, Khurana S, et al. A live attenuated influenza A (H5N1) vaccine induces long-term immunity in the absence of a primary antibody response. J Infect Dis 2014; 209:1860-9.
21. Waalen K, Kilander A, Dudman SG, Ramos-Ocao R, Hungnes O. Agedependent prevalence of antibodies cross reactive to the influenza A (H3N2) variant virus in sera collected in Norway in 2011. Euro Surveill 2012; 17:pii:20170.
22. Keitel WA, Cate TR, Couch RB, Huggins LL, Hess K. Efficacy of repeated annual immunization with inactivated influenza virus vaccine over a five year period. Vaccine 1997; 15:1114-22.
23. Levine M, Beattie BL, McLean DM, Corman D. Characterization of the immune response to trivalent influenza vaccine in elderly men. J Am Geriatr Soc 1987; 35:609-15.
24. Frey SE, Bernstein DI, Gerber MA, et al. Safety and immunogenicity of 2009 H1N1 vaccine in children. J Infect Dis 2012; 15:1-10.
25. El Sahly HM, Davis C, Kotloff K, et al. Higher antigen content improves the immune response to 2009 H1N1 influenza vaccine in HIV-infected adults: a randomized clinical trial. J Infect Dis 2012; 205: 703-12.
26. Keitel WA, Atmar RL, Cate TR, et al. Safety of high-doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med 2006; 166:1121-7.
27. DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med 2014; 371:635-45.